| Title: |
Management of hepatocellular carcinoma: a study on 240 patients in a single referral center |
| Authors: |
Ivanova, Irina Ivanova; Banova, Sonya; Mirchev, Milko; Kotzev, Iskren; Zlatarov, Alexander; Tonev, Anton; Kolev, Nikola; Chakarov, Svetomir; Bachvarov, Chavdar; Balev, Boyan; Bocheva, Yana; Tzaneva, Maria |
| Contributors: |
Medical University "Dr.Paraskev Stoyanov" - Varna |
| Source: |
Scripta Scientifica Medica; Vol 50, No 2 (2018); 19-26 ; 1314-6408 ; 0582-3250 |
| Publisher Information: |
Medical University of Varna |
| Publication Year: |
2018 |
| Collection: |
Varna Medical University Press: Journals |
| Subject Terms: |
Hepatocellular Carcinoma; Hepatitis B; Hepatitis C; Surveillance; Survival |
| Description: |
Introduction: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death globally. Our study aimed to provide an understanding of the risk factors, pattern and management of HCC in a real-life practice.Materials and Methods: Two hundred and forty consecutive patients with HCC were evaluated for an 11-year period (from 2006 to 2016). During the last 5 years the patients were followed up prospectively from the time of the diagnosis to their death. Results: A hundred and seventy-two males and 68 females (mean age 66.4 ± 10.3 and 62.4 ± 9.5 years, respectively) were included in the observation. Hepatitis B virus (HBV) infection accounted for 40.4% and hepatitis C virus (HCV) infection - for 25.8% of the aetiology of liver disease. Cirrhosis is a baseline condition in 82%. HCC was found to be a first complication of liver disease in 2/3 of the studied patients. Using Barcelona Clinic Liver Cancer staging system HCC can be categorised as: stage 0 (n=3); stage A (n=32); stage B (n=52); stage C (n=75) and stage D (n=103). Therefore, the prevalence of very early and early HCC was 13%. Radical therapy (resection or ablation) was recommended in 28% of the patients. Importantly, 18 of 55 (32.7%) patients after surgical resection were followed for more than 3 years without tumour relapse. The median survival, based on the main treatment was: 36 months after surgical resection; 24 months after ablation; 10.5 months for patients on Sorafenib; 9.5 months after TACE and only 3 months for palliative care. Conclusion: Our study confirms the observed trends in underlying diseases, the heterogeneity of survival and underscores the need of early diagnosis of HCC. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://journals.mu-varna.bg/index.php/ssm/article/view/4441/4814; https://journals.mu-varna.bg/index.php/ssm/article/downloadSuppFile/4441/1971; https://journals.mu-varna.bg/index.php/ssm/article/downloadSuppFile/4441/1972; https://journals.mu-varna.bg/index.php/ssm/article/downloadSuppFile/4441/1973; https://journals.mu-varna.bg/index.php/ssm/article/downloadSuppFile/4441/1974; https://journals.mu-varna.bg/index.php/ssm/article/downloadSuppFile/4441/1975; https://journals.mu-varna.bg/index.php/ssm/article/downloadSuppFile/4441/1976; https://journals.mu-varna.bg/index.php/ssm/article/downloadSuppFile/4441/1977; https://journals.mu-varna.bg/index.php/ssm/article/downloadSuppFile/4441/1978; https://journals.mu-varna.bg/index.php/ssm/article/downloadSuppFile/4441/1979 |
| DOI: |
10.14748/ssm.v50i2.4441 |
| Availability: |
https://journals.mu-varna.bg/index.php/ssm/article/view/4441; https://doi.org/10.14748/ssm.v50i2.4441 |
| Rights: |
Всички публикации на Scripta Scientifica Medica са лицензирани под Creative Commons Attribution 3.0 License. ; All work by Scripta Scientifica Medica is licensed under a Creative Commons Attribution 3.0 License. |
| Accession Number: |
edsbas.7C89BFD0 |
| Database: |
BASE |